Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between with United ...

A five-item tool using spirometry and basic clinical data may predict recurrent tuberculosis with moderate accuracy, helping ...

Gilead Sciences, Inc. (GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to combat AIDS, ...

Humans have been getting infected by ancient bacteria and viruses for at least 37,000 years. Now, for the first time, ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalised plans to ...

Evotec SE (NASDAQ: EVO) is among the 13 Best German Stocks to Invest in Now. The company’s shares have gained over 9% in the ...

US antivirals specialist Gilead Sciences today announced a strategic partnership agreement with the Global Fund to Fight AIDS ...

The centerpiece of the acquisition is Ohtuvayre, a treatment for chronic obstructive pulmonary disease that secured U.S. approval last year. The drug’s commercial launch has exceeded Wall Street ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...